Dr Elizabeth Plimack talks to ecancer in an online interview for the ASCO virtual meeting 2020 about the HCRN: GU16-260 study.
This was a phase II study of nivolumab and salvage nivolumab ipilimumab in treatment-naïve patients with advanced renal cell carcinoma.
Dr Plimack outlines the reasoning behind the study, and the results which showed a lack of response from the addition of ipilimumab.